Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Umitrelimorgene autodencel by Immunomic Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
Umitrelimorgene autodencel is under clinical development by Immunomic Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to...